Maraviroc Waymade

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral tablet for oral administration. It is indicated for the treatment of HIV‑1 infection, where it blocks the CCR5 co‑receptor to prevent viral entry into CD4⁺ T‑cells, helping to control viral replication in adults and adolescents.

GNH USA supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this antiretroviral agent across global markets.

Maraviroc is used to manage HIV‑1 infection by targeting the CCR5 co‑receptor pathway.

- HIV‑1 infection (treatment‑naïve adults): reduces viral load when combined with standard antiretroviral regimens. - HIV‑1 infection (treatment‑experienced adults): offers an alternative mechanism for patients with resistant virus. - HIV‑1 infection (CCR5‑tropic virus): specifically effective when the virus utilizes the CCR5 co‑receptor.

Maraviroc may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - QT interval prolongation: potential cardiac arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety measures.

- Assess CCR5 tropism: confirm the virus uses the CCR5 co‑receptor before prescribing. - Monitor liver function: obtain baseline tests and repeat periodically. - Evaluate for drug interactions: review concomitant medications that affect CYP3A4. - Observe for hypersensitivity: discontinue if severe allergic reactions occur. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Maraviroc can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin): may increase Maraviroc levels. - Azole antifungals (e.g., ketoconazole, itraconazole): can raise plasma concentrations. - Amiodarone: risk of additive QT prolongation.

Moderate Interactions (Monitor Closely): - Rifampin: potent CYP3A4 inducer that may reduce efficacy. - Certain statins (e.g., simvastatin): may require dose adjustment due to metabolic overlap.